EGFR and non-small cell lung carcinoma: While EGFR tyrosine kinase inhibitors (TKIs) are effective as first-line treatments for advanced EGFR-mutated non-small-cell lung cancer (NSCLC), the development of acquired resistance limits their long-term efficacy [6,7].